Are new variants of psoriasis therapy (IL‐17 inhibitors) safe?
- 13 June 2019
- journal article
- review article
- Published by Wiley in International Journal of Dermatology
- Vol. 58 (12) , 1360-1365
Abstract
Psoriasis is a chronic, recurrent, inflammatory, and proliferative skin disease. Its etiology has not yet been fully assessed, but undoubtedly it is a multifaceted disease. The key role in its pathomechanism is played by genetic, immunologic, and environmental factors and stress. If traditional methods of psoriasis treatment (phototherapy, methotrexate, retinoids, cyclosporine A) fail, we reach for the following biopharmaceuticals – infliximab, etanercept, adalimumab, or ustekinumab. However, genetic engineering progress discovers new possibilities – the pending clinical trials involve IL‐17, IL‐23 antagonists, PDE4 and ‐3 and ‐1. Psoriasis etiopathogenesis mainly involves the IL‐17A, IL‐17F, and IL‐17A/F subtypes, which affect the keratinocytes. The biological therapy molecularly oriented with the antagonists of interleukin 17 is based mainly on the influence onto the cytokine in the manner that prevents it from binding with the receptor. Three biopharmaceuticals are currently under third phase studies: two fully humanized antibodies neutralizing IL‐17 – ixekizumab and secukinumab, and one human monoclonal antibody, brodalumab. The below work will be devoted to the analysis of possible undesirable symptoms, which were observed during the studies. We will try to review the latest literature concerning the most important clinical trials conducted in many centers.Keywords
This publication has 24 references indexed in Scilit:
- Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)Journal of the European Academy of Dermatology and Venereology, 2014
- Immunology of PsoriasisAnnual Review of Immunology, 2014
- In psoriasis, levels of hope and quality of life are linkedArchives of Dermatological Research, 2014
- The role of IL-17 in psoriasisJournal of Dermatological Treatment, 2014
- Systemic Therapies for Psoriasis: An Evidence-Based UpdateAmerican Journal of Clinical Dermatology, 2014
- Le psoriasis : physiopathologie et immunogénétiquePathologie Biologie, 2014
- Advances in treating psoriasisF1000Prime Reports, 2014
- IL-17 targeted therapies for psoriasisExpert Opinion on Investigational Drugs, 2013
- An Observational Study on the Obesity and Metabolic Status of Psoriasis PatientsAnnals of Dermatology, 2013
- Treatment of Psoriasis and Psoriatic ArthritisBioDrugs, 2013